Emerging Role of MiR-192-5p in Human Diseases

Fu-jia Ren1†, Yao Yao2†, Xiao-yu Cai3 and Guo-ying Fang1*

1Department of Pharmacy, Hangzhou Women’s Hospital (Hangzhou Maternity and Child Health Care Hospital), Hangzhou, China, 2Department of Pharmacy, Women’s Hospital School of Medicine, Zhejiang University, Hangzhou, China, 3Department of Pharmacy, Hangzhou First People’s Hospital, Hangzhou, China

MicroRNAs (miRNAs) are a type of small non-coding RNAs that play an essential role in numerous biological processes by regulating the post-transcriptional expression of target genes. Recent studies have demonstrated that miR-192-5p, a member of the miR-192 family, participates in several human diseases, especially various cancers, including cancers of the lung, liver, and breast. Importantly, the levels of miR-192-5p are abundant in biofluids, including the serum and urine, and the exosomal levels of miR-192-5p in circulation can aid in the diagnosis and prognosis of various diseases, such as chronic hepatitis B (CHB) infection disease. Notably, recent studies suggest that miR-192-5p is regulated by long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs). However, there are no comprehensive overviews on the role of miR-192-5p in human diseases. This review discusses the significant studies on the role of miR-192-5p in various human diseases, with special emphasis on the diseases of the respiratory and digestive systems.

Keywords: miR-192-5p, human diseases, Cancers, respiratory system, digestive system

INTRODUCTION

MicroRNAs (miRNAs) are short (18–25 nt), noncoding, single-stranded RNAs, that regulate the expression of target genes by binding to the 3′-untranslated region (UTR) or open reading frames (ORFs) of the target mRNA for inducing translational repression or mRNA degradation in animals (Jonas and Izaurralde, 2015). However, some studies have reported that certain miRNAs facilitate gene expression (Place et al., 2008). In particular, many studies have demonstrated that miRNAs play a role in numerous cellular processes, including cellular differentiation, oxidative stress, apoptosis, and autophagy. Increasing evidence suggests that a large number of miRNAs are dysregulated in various human diseases, especially cancers. These studies indicate that miRNAs could either act as oncogenes or tumor suppressors, despite the fact the miRNAs are generally downregulated in tumors, compared to normal tissues (Lu et al., 2005). Meaningfully, the miRNAs present in biological biofluids are potential non-invasive diagnostic and prognostic biomarkers of various human diseases. Moreover, accumulating studies highlight that exosomal miRNAs in biofluids as essential participants in tumorigenesis (Ingenito et al., 2019). Due to the nature delivery systems of exosomes between cells, some therapeutic miRNAs can be appropriately packaged in exosomes to target specific recipient cells. Intriguingly, increasing reports indicate that the expression levels of miRNAs are regulated by long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) (Cai et al., 2019; Liu et al., 2019; Sun et al., 2020). Noteworthily, cytoplasmic lncRNAs or circRNAs frequently possess potential sites for binding to certain miRNAs, and can repress miRNA function by acting as miRNA sponges in tumor development (Shi et al., 2013; Kulcheski et al., 2016). Therefore, miRNAs, as post-transcriptional gene regulators, have therapeutic and application potential.
It is worth mentioning that miR-192-5p is a conserved miRNA, which is abundant in the liver, and plays important roles in numerous hepatic disorders, including chronic hepatitis B (CHB), drug-induced liver injury, nonalcoholic fatty liver disease (NAFLD), and hepatocellular carcinoma (HCC) (Nielsen et al., 2018; Roy et al., 2016; Wen et al., 2015). Importantly, increasing evidence suggests that miR-192-5p is closely involved in different physiological and pathological processes, especially in the incidence of cancer. Moreover, exosomal miR-192-5p in biological fluids may be a potential biomarker of disease progression, such as NAFLD (Liu et al., 2019). Interestingly, the expression of miR-192-5p is regulated by diverse factors, including p53 and TGF-β (Chen et al., 2016; Puppo et al., 2016). For instance, Puppo and coworkers reported that TGF-β represses the expression of KHSRP, a component of the ribonucleoprotein complex, which controls the maturation of miR-192-5p and promotes the expression of some epithelial-to-mesenchymal transition (EMT) factors (Figure 1) (Puppo et al., 2016). Besides, IncRNAs and circRNAs can also act as upstream regulators that modulate the expression of miR-192-5p (Cai et al., 2019; Sun et al., 2020). A recent study by Sun and coworkers revealed that the opposite strand/antisense transcript 1 (KCNQ1OT1) IncRNA inhibits sepsis-induced myocardial injury by regulating the miR192-5p/X-linked inhibitor of apoptosis (XIAP) axis (Sun et al., 2020). Zhao and coworkers demonstrated that the FTX IncRNA promotes the progression of colorectal cancer (CRC) by targeting the miR-192-5p/EIF5A2 axis (Zhao et al., 2020b). Cai and coworkers reported that circHIPK3 promotes hyperglycemia and insulin resistance by acting as a sponge for miR-192-5p, which subsequently induces the expression of the forkhead box O1 (FOXO1) protein (Cai et al., 2019). Therefore, miR-192-5p is a critical miRNA for the progression of human diseases, which can be regulated by other vital regulatory molecules and subsequently affect the expression of downstream genes (Figure 1).

This review systematically summarizes recent studies on the functions and mechanisms underlying the role of miR-192-5p in different physiological processes and human diseases (Table 1). The potential regulatory role of miR-192-5p in diseases of the respiratory (Figure 2) and digestive systems (Figure 3) are emphasized, which would enable a comprehensive understanding of the role of miR-192-5p in the occurrence of certain diseases and present novel directions for future research.

**Biogenesis of miR-192-5p**

Data from the miRbase database reveal that there are approximately 80 different human miRNA precursors, that produce two mature miRNAs, namely, the 5’ and 3’ strands, with different seed sequences and target mRNAs to which they bind. Human miR-192 is derived from a coding gene located on chromosome 11, which produces two mature transcripts, miR-192 (miR-192-5p) and miR-192* (miR-192-3p) (Bartel, 2004; Krattinger et al., 2016). Both miR-192-5p and miR-192-3p...
inhibits the translation of target mRNAs by targeting the 3′-UTR in different biological processes (Figure 1).

Numerous studies have investigated the roles of miR-192-5p; however, the functions of miR-192-3p are poorly explored. The study by Mysore and coworkers emphasized the important role of miR-192-3p in adipocyte differentiation and lipid homeostasis. First, they found an interesting phenomenon that miR-192-3p in the visceral adipose tissue (VAT) of obese patients is negatively correlated with the levels of serum triglyceride (TG). Further mechanism studies have demonstrated miR-192-3p represses the adipocytic differentiation of human Simpson–Golabi–Behmel syndrome (SGBS) adipocytes by targeting aldehyde dehydrogenase 3 family member A2 (ALDH3A2) and stearoyl coenzyme A desaturase 1 (SCD), which is indicated by a significant reduction in the TG content and the decreased expression of the adipocyte marker proteins, aP2 and perilipin 1 (Mysore et al., 2016). Additionally, miR-192-5p and miR-192-3p have a synergistic role in downregulating the expression of farnesoid X receptor (FXR) and the target genes of FXR in the liver and colon cancer-derived cell lines. However, miR-192 has differential effects on the expression of FXR in Huh7 and Caco-2 cells (Krattinger et al., 2016). Sometimes they work synergistically together and sometimes individually,

### TABLE 1 | miR-192-5p in different human diseases. The asterisk (*) represents controversial.

| Human system | Disease type | Role | Target | References |
|--------------|--------------|------|--------|------------|
| Respiratory  | Asthma       | Represses the differentiation of T follicular helper cell | CXCR5 | Zhang et al. (2018), Lou et al. (2020), and Yamamoto et al. (2012) |
|              |              | Alleivates airway remodeling and autophagy | MMP-16 and ATG7 | Ye et al. (2015), Zou et al. (2019), Jin et al. (2015), and Kumar et al. (2020) |
| Lung cancer  |              | Suppresses the tumor growth in NSCLC cell lines | XIAP | Ye et al. (2015), Zou et al. (2019), Jin et al. (2015), and Kumar et al. (2020) |
|              |              | Inhibits the proliferation, migration and invasion of lung cancer cells | TRIM44 | Ye et al. (2015), Zou et al. (2019), Jin et al. (2015), and Kumar et al. (2020) |
| Digestive    | HCC*         | Promotes proliferation and metastasis of HCCLM3 cells | SEMA3A | Yan-Chun et al. (2017), Gu et al. (2019), and Zhu et al. (2019) |
|              |              | Inhibition of miR-192-5p promotes CSC populations | PABPC4 | Yan-Chun et al. (2017), Gu et al. (2019), and Zhu et al. (2019) |
|              |              | Inhibits the progression of HCC. | TRIP13 | Yan-Chun et al. (2017), Gu et al. (2019), and Zhu et al. (2019) |
| NAFLD        |              | Inhibit lipid synthesis | SCD-1 | Liu et al. (2017), Li et al. (2019), Lee et al. (2019), and Prola et al. (2015) |
| Liver injury |              | Promote the M1 macrophage polarization | Rictor | Roy et al. (2016), Zhang et al. (2020), Yan et al. (2014), and Church et al. (2016) |
| Colon cancer |              | Positively correlated with injury degree | Zeb2 | Roy et al. (2016), Zhang et al. (2020), Yan et al. (2014), and Church et al. (2016) |
|              |              | Promote DMF-induced hepatotoxicity | NOB1 | Roy et al. (2016), Zhang et al. (2020), Yan et al. (2014), and Church et al. (2016) |
| Colon cancer |              | Represses cell glycolysis | SRPX2 | Zhao et al. (2018), Huang et al. (2020) |
|              |              | Inhibits cell proliferation | RhoA-ROCK-LIMK2 pathway | Zhao et al. (2018), Huang et al. (2020) |
| Gastric cancer |              | Reverses cisplatin resistance | ERCC3 and ERCC4 | Xie et al. (2019), Tavakolian et al. (2020) |
| Gastric cancer |              | Aggravates the arrhythmia | SCN5A | Zhao et al. (2015) |
| Circulation | Antrhythmic diseases | | | |
| Myocardial injury | Kidney injury | Promotes apoptosis of cardiomycyte | FABP3 | Zhang et al. (2017), Sun et al. (2020) |
| Urinary | Promotes collagen deposition in diabetic kidney | S1P1 | Kato et al. (2007), Baker et al. (2019), and Chen et al. (2016) |
| Reproductive | Breast cancer | Negatively correlates with ERα expression | LY6K | Kim et al. (2016), Chen et al. (2018), Fang et al. (2018), and Zhang et al. (2019) |
|              | Prostate cancer | Promotes proliferation of prostate cancer cells | UBASH3B | Chen et al. (2019), Wang et al. (2019) |
| Endocrine | Diabetes | Represses insulin resistance | FOXO1 | Cai et al. (2019), Argyropoulos et al. (2015), Jaeger et al. (2018), Mo et al. (2017), Nunez Lopez et al. (2019), and Wu et al. (2015) |
| Nervous | Depression | Rescues cognitive impairment and repair neural function | Rbln-2 | Tang et al. (2019) |
| Nervous | Left sciatic nerve injury | Promotes neuronal apoptosis | XIAP | Liu et al. (2020) |
| Motor | PD | Represses cell viability and induce apoptosis | Unknown | Kang et al. (2019) |
| Motor | RA | Delays inflammatory response | RAC2 | Zheng et al. (2020), Li et al. (2017) |
| Osteosarcoma | | Represses the proliferation, migration and invasion of osteosarcoma cells | USP1 | Zhou et al. (2018) |
underscoring their different relationships to each other in different pathological conditions. Although this review primarily discusses the role of miR-192-5p in human diseases, the additive effect of the 3′-transcript should not be overlooked.

**Physiological Roles of miR-192-5p**

It has been reported that miR-192-5p is abundant in the liver, where it promotes the development of the liver, cellular trans-differentiation, and coordinates energy metabolism (Raut and Khanna, 2016). Moreover, the levels of miR-192-5p are negatively correlated with the expression of the multidrug transporter, ATP binding cassette transporter subfamily C member 3 (ABCC3), in the human intestine, signifying that miR-192-5p may influence drug absorption (Bruckmueller et al., 2017). We can suspect that miR-192-5p may play an important role in the normal liver, the largest digestive glands, and intestines in the human body, but the current studies are not sufficient and more data are needed to support and improve this inference.

A recent miRNA profiling study suggested that miR-192-5p may be implicated in the developmental competence of female oocytes, indicating that miR-192-5p has a potential role in the reproductive system (Woo et al., 2018). It is widely acknowledged that uterine receptivity is vital for embryo implantation, and it starts with the transformation of the luminal epithelium (Murphy, 2004). Interestingly, one study by Liang and coworkers reported that miR-192-5p is downregulated rapidly in the uteri of mice before implantation, and retains at low expression levels during and after implantation. By performing in situ hybridization assay, they found miR-192-5p is expressed in the endometrial epithelium, and dysregulation of miR-192-5p disturbed the performance of the luminal epithelium, leading to
inadequate receptivity. This study emphasized the physiological role of miR-192-5p in the mouse uterus is to keep the nonreceptive state of epithelial cells and impede their transformation to the receptive state (Liang et al., 2020). Therefore, miR-192-5p may be a vital regulator in the orderly process of the reproductive system.

Researchers have also demonstrated that miR-192-5p is involved in regulating blood pressure and heart rate. Thus, miR-192-5p plays a crucial role in the vital biological processes of human physiology. In particular, overwhelming data have reported that miR-192-5p regulates oxidative stress, cellular proliferation, apoptosis, and inflammatory responses (Caserta et al., 2016; Fuschi et al., 2017). Given its important role in human physiological processes and cellular processes, the dysregulation of miR-192-5p may contribute to the genesis of human diseases.

MIR-192-5P IN HUMAN DISEASES

Diseases of the Respiratory System

Asthma

Asthma is a common respiratory disorder, characterized by variable respiratory symptoms and variable airflow limitation, that affects around 334 million people worldwide (Papi et al., 2018). Miserably, the prognosis of asthma remains poor, despite the application of several strategies to the treatment of asthma (Gibeon and Menzies-Gow, 2013). Fortunately, increasing evidence suggests that miR-192-5p could be a potential target for the treatment of asthma. In 2012, Yamamoto and coworkers first identified that the levels of miR-192 are significantly downregulated in the peripheral blood of asthmatic individuals undergoing an allergen inhalation challenge compared to those of healthy controls (HCs) (Yamamoto et al., 2012), suggesting a potential role of miR-192-5p in asthma. Subsequently, another study demonstrated that the levels of miR-192 are lower in children with asthma compared to those of HCs, and further experimental studies confirmed that miR-192 represses the differentiation of follicular T-helper cells by targeting C-X-C chemokine receptor type 5 (CXC RS5) in childhood asthma (Zhang et al., 2018). Moreover, Lou and coworkers demonstrated that the levels of miR-192-5p are decreased in asthmatic mice, and the overexpression of miR-192-5p alleviates airway remodeling and autophagy in asthma by targeting matrix metalloprotease-16 (MMP-16) and autophagy-related 7 (ATG7) in vitro and in vivo (Lou et al., 2020). In general, these four studies revealed miR-192-5p may be a potential regulator in the progression of asthma, and further studies are needed to elucidate the deep mechanisms.

Nasopharyngeal Carcinoma

Nasopharyngeal carcinoma (NPC) is an epithelial carcinoma originating from the nasopharyngeal mucosal lining, which is regarded as a considerable health burden in low resource countries, exhibiting unbalanced geographical distribution, including Southeastern Asia (Chua et al., 2016). There are approximately 129000 new cases of NPC in 2018, according to the International Agency for Research on Cancer (Chen YP et al., 2019). Epstein–Barr virus (EBV) infections are correlated with the pathogenesis of NPC, and detection of plasma EBV DNA has been utilized for population screening, prognostication, predicting treatment response for therapeutic adaptation, and disease surveillance (Chen YP et al., 2019). In 2020, a study on miRNA profiling in the serum of patients with NPC revealed that 30 miRNAs were aberrantly expressed in the serum. Among these, miR-192-5p was found to be upregulated in the serum and tissues of patients with NPC, however, there was no significant difference in miR-192-5p expression in the exosomes. To study the diagnostic applications of identified miRNAs, researchers found that the expression of miR-192-5p is downregulated in EBV-positive patients, but upregulated in EBV-negative patients, compared to that of normal controls (NCs), suggesting that the status of EBV infection can influence miR-192-5p expression. Using a logistic regression model for evaluating the prediction probability of NPC, researchers have constructed a panel of five miRNAs (let-7b-5p, miR-140-3p, miR-192-5p, miR-223-3p, and miR-24-3p), which has significantly high sensitivity and specificity for discriminating patients with NPC from healthy individuals. However, survival analysis revealed that the level of miR-192-5p is less related to the clinical outcomes of the patients. Therefore, further studies are necessary for elucidating the function and mechanism underlying the role of miR-192-5p in NPC for exploring a valuable biomarker for predicting NPC (Zou et al., 2020).
the expression of c-Myc and the Wnt/β-catenin pathway in two NSCLC cell lines, A427 and A549 (Pan et al., 2020). It is widely acknowledged that approximately 50%–70% of patients with lung cancer suffer from bone metastasis. In 2019, Zou and coworkers demonstrated that the expression of miR-192-5p is downregulated in the serum of patients with lung cancer and lung cancer cell lines, while the expression of tripartite motif 44 (TRIM44) shows an opposite tendency. Further studies have demonstrated that miR-192-5p inhibits the proliferation, migration, and invasion of lung cancer cells by targeting TRIM44 in vitro and in vivo, particularly by repressing bone metastasis (Zou P et al., 2019). Coincidently, small RNA sequencing by Kumar and coworkers demonstrated that the expression of miR-192-5p is reduced in the serum of Indian patients with NSCLC, and further study revealed that the expression of miR-192-5p is correlated with the sex of the patient (Kumar et al., 2020). Conclusively, miR-192-5p may be a potential therapeutic biomarker of NSCLC and a potential target of turmeric, with good development potential.

It is worth mentioning that NSCLC is a heterogeneous disease, which can be divided into 2 broad histologic subtypes, namely, the squamous cell carcinoma (LUSC) and adenocarcinoma (LUAD) subtypes (Lim et al., 2020). Recently, a plasma exosome miRNA profiling study performed on six healthy individuals, six patients with LUAD before surgery, and six patients after 7 days of surgery indicated that the expression of miR-192-5p is sharply increased in the plasma exosomes of patients with LUAD, where a high abundance of miR-192-5p is indicative of poor survival rates. Besides, the study demonstrated that miR-192-5p is significantly downregulated post-surgery, suggesting a tumor promotive role of miR-192-5p in LUAD (Xue et al., 2020). These results are controversial owing to the paradox between the inference of this study with that of previous studies on the anti-cancer effect of miR-192-5p in NSCLC. Therefore, further studies are urgently required for elucidating the potential role of miR-192-5p in lung cancer.

**Diseases of the Digestive System**

**Hepatic Disorders**

It has been reported that miR-192-5p is abundantly expressed in hepatic tissues, and is regarded as a potential biomarker for various hepatic disorders (Figure 4) (Iguchi et al., 2017; Bushel et al., 2018; Oda et al., 2018). Previously, an important study demonstrated that the expression of miR-192-5p markedly increases during the development of the human liver, which induces hepatic trans-differentiation from human umbilical cord Wharton’s jelly derived mesenchymal stem cells (hUC-MSCs), indicating the crucial role of miR-192-5p in the physiological processes of the human liver (Tzur et al., 2009; Raut and Khanna, 2016). Chronic hepatitis B (CHB) infection leads to the development of severe liver diseases, such as hepatic cirrhosis and HCC. In 2014, researchers first identified that miR-192-5p is overexpressed in both the sera and HBsAg-particles of CHB by miRNA profiling analysis of inactive-carriers (IC) and patients of CHB, suggesting an emerging role of miR-192-5p in CHB (Brunetto et al., 2014). Subsequently, another research team identified that miR-192-5p is present in hepatoma-derived extracellular vesicles and is abundantly expressed in

![Figure 4](image-url)
HBeAg-positive patients compared to HBeAg-negative patients, signifying miR-192-5p is associated with HBeAg-status (van der Ree et al., 2017). Moreover, in 2018, one study by Nielsen and coworkers demonstrated that the replication of HBV is correlated with the in vitro expression of miR-192-5p in the HepG2 cell model system, and overexpression of miR-192-5p by mimics reduces the protein level of pro-apoptotic BIM and suppresses endoplasmic reticulum (ER) stress-induced apoptosis in HepG2 cells (Nielsen et al., 2018). Summarily, miR-192-5p may contribute to the development of HBV-related liver diseases by influencing HBeAg-status. However, Tan and coworkers found the serum level of miR-192-5p is significantly reduced in cirrhosis that evolves into hepatocellular carcinoma, during hepatitis B virus infection (Tan et al., 2015). Therefore, we suspected that circulating miR-192-5p is probably a flexible molecule, and contributes to the progression of various HBV-related liver diseases.

According to the GLOBOCAN 2018 database, liver cancer is the sixth most commonly diagnosed cancer and the fourth leading cause of cancer death. HCC (comprising 75%–85% of cases) is the most frequent primary liver cancer, and is closely related to chronic HBV infection (Bray et al., 2018). Notably, the emerging role of miR-192-5p in HCC has been gradually investigated. In 2015, a multicenter three-phase study indicated that miR-192-5p is a potential early serum biomarker for the detection of HCC (Wen et al., 2015). Subsequently, a study by Li and coworkers revealed that miR-192-5p can promote the proliferation and metastasis of the HCC cell line, HCCCLM3, by targeting semaphorin 3A (SEMA3A), a potent inhibitor of tumor angiogenesis in different cancers (Yan-Chun et al., 2017). It is widely acknowledged that cancer stem cells (CSCs) are closely related to the initiation, metastasis, recurrence, and chemo-resistance of various tumors, especially in HCC (Oikawa, 2016). In contrast to the research presented above, the expression of miR-192-5p is downregulated in CSC HCC and the inhibition of miR-192-5p promotes the development of multiple populations of CSCs and CSC-related features by targeting PABPC4 (Gu et al., 2019). Mechanistically, the miR-192 promoter is hyper-methylated, which leads to the transcriptional repression of miR-192-5p in HCC cell lines and primary CSC HCC (Gu et al., 2019). Besides, Zhu and coworkers reported that miR-192-5p is an upstream regulator of thyroid hormone receptor interactor 13 (TRIP13), a promising oncogene in HCC, by directly targeting the 3′-UTR of TRIP13 mRNA, thereby inhibiting the progression of HCC (Zhu et al., 2019). Interestingly, the expression of miR-192-5p is also regulated by other molecules in HCC, including circRNA, although increasing evidence has demonstrated that numerous molecules are influenced by miR-192-5p (Qiu et al., 2019). As the role of miR-192-5p in HCC is controversial, it is difficult to define miR-192-5p as an oncogene or tumor suppressor. Further studies are necessary for elucidating the function and mechanism underlining the role of miR-192-5p in HCC.

In 2015, a global serum miRNA profiling study revealed that miR-192-5p could be a potential regulator of NAFLD (Pirola et al., 2015). Then, a study by Liu and coworkers demonstrated that miR-192-5p is downregulated in high-fat diet (HFD) induced rat NAFLD, and overexpression of miR-192-5p inhibits lipid synthesis by targeting stearoyl-CoA desaturase 1 (SCD-1) in Hepa7 cells exposed to PA (Liu XL et al., 2017). Interestingly, a recent study the same research team reported that circulating and hepatocyte-derived exosomal miR-192-5p can contribute to the inflammatory response in NAFLD. First, they identified that the levels of miR-192-5p in the serum of NAFLD patients are positively correlated with pathological features of the liver, including AST, ALT, the occurrence of hepatic steatosis, and activity score. Coincidentally, a similar phenomenon was observed in rats with HFD-induced NAFLD. Functionally, the serum levels of miR-192-5p are related to the phenotypic variation of macrophages, and exosomal miR-192-5p secreted by lipotoxic hepatocytes promotes the activation of M1 macrophages (CD11b+ CD86+) and increases the expression of the M1 marker genes, iNOS, IL-6, and TNF-α. Mechanistically, hepatocyte-derived exosomal miR-192-5p represses the expression of the rapamycin-insensitive companion of mammalian target of rapamycin (Rictor) protein by targeting the 3′-UTR of its mRNA, which subsequently inhibits the activation of AKT and promotes the activation of FOXO1 (Liu et al., 2019). More importantly, a recent study reported that the consumption of blackcurrant (Ribes nigrum) in CSBL/6j mice prevents HFD-induced nonalcoholic steatohepatitis (NASH), as indicated by the lower infiltration of macrophages, especially M1 macrophages, and the reduced circulating levels of miR-122-5p and miR-192-5p (Lee et al., 2019). Therefore, miR-192-5p plays an important role in lipid metabolism and inflammation in NAFLD, making it a promising diagnostic target for NAFLD, and further mechanistic studies are needed to perform in order to clarify its meaningful role.

Additionally, miR-192-5p also plays a role in various liver injuries induced by damaging factors. A study by Yan and coworkers on the profile of circulating miRNAs revealed that the levels of miR-192-5p are significantly upregulated in mice after 28 days of exposure to perfluorooctanoic acid (PFOA), a known hepatotoxic compound with industrial and commercial uses (Yan et al., 2014). Moreover, the levels of miR-192-5p were also upregulated in the serum of mice with hepatic ischemia and reperfusion (I/R), and carbon tetrachloride (CCL4)-induced liver injury, as well as in patients with hepatic injury. In contrast, the study by Roy et al. reported that the levels of miR-192-5p were downregulated in the injured liver tissues of mice and human subjects, specifically in the hepatocytes, while there are no variations in the levels of miR-192-5p in other non-parenchymal cells. The knockdown of miR-192-5p repressed H2O2-induced cell death of Hepa1-6 cells by targeting Zeb2, suggesting lower levels of miR-192-5p in hepatocytes after acute liver injury may exhibit a protective action. In this study, it is noteworthy that the serum levels of miR-192-5p were positively correlated with the AST/ALT ratio in TUNEL-positive cells, and the levels of miR-122, a potent marker of liver injury and hepatic cell death (Roy et al., 2016). Therefore, miR-192-5p may be a promising target in predicting acute liver injuries. Besides, it has also been indicated that miR-192-5p is a potential biomarker of drug-induced hepatobiliary injury and biliary hyperplasia in rats.
factors, and maybe a potential biomarker. An important role in liver injury induced by different pathologic (NOB1) (Zhang et al., 2020). Conclusively, miR-192-5p plays an apoptotic gene, NIN1/RPN12 binding protein 1 homolog (NOB1) (Zhang et al., 2020). Conclusively, miR-192-5p plays an important role in liver injury induced by different pathologic factors, and maybe a potential biomarker.

**Diseases of the Digestive Tract**

Apart from hepatic disorders, studies on miR-192-5p have also been performed in other diseases of the digestive tract, including esophageal, colorectal, and gastric cancers (Della Vittoria Scarpati et al., 2014; Huang et al., 2017; Xie et al., 2019). Esophageal cancer (EC) ranks seventh in terms of incidence (572,000 new cases) and sixth in mortality overall (509,000 deaths), based on the GLOBOCAN 2018 database, which mainly consists of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) (Bray et al., 2018). Notably, the levels of circulating miR-192-5p increased in both ESCC and EAC, suggesting a promising regulatory role of miR-192-5p in EC (Bansal et al., 2014; Huang et al., 2017). Further studies are essential for investigating its function and mechanism in EC. Physiologically, miR-192-5p is more abundantly expressed in mucosal samples from the small intestine than in those of the large intestine, while the expression of ABCC3, an intestinal transporter, exhibits an opposite tendency in the large and small intestines. By employing TargetScan and MicroCosm Targets version 5, it has been revealed that miR-192-5p can bind to the 3′-UTR of ABCC3 mRNA, thereby inhibiting the expression of the ABCC3 protein (Bruckmueller et al., 2017). Given the independent role of miR-192-5p in the intestine, the dysregulation of miR-192-5p may be related to the genesis of intestinal diseases. Guo and coworkers reported that the levels of miR-192-5p is downregulated in the inflamed terminal ileal mucosa of adults with active Crohn’s disease (CD), and is significantly increased following exclusive enteral nutrition (EEN) therapy (Guo et al., 2015). Additionally, the levels of miR-192-5p are reduced in the duodenum of adults with CD, and are negatively correlated with the expression of C-X-C motif chemokine ligand 2 (CXCL2) and nucleotide binding oligomerization domain containing 2 (NOD2) genes, which are involved in innate and adaptive immunity in Marsh 3C patients (Magni et al., 2014). Intriguingly, the expression of miR-192-5p showed a similar pattern in pediatric celiac disease, however, there are no variations in the expression of NOD2 and CXCL2. Alternatively, the expression of MAD2L1, another target gene associated with cell cycle control, is markedly increased. Therefore, miRNA-regulated gene expression may be disparate in patients with celiac disease, depending on the age of presentation (Buoli Comani et al., 2015). It has been demonstrated that the expression of miR-192-5p is higher in cancer tissues compared to that of para-carcinoma tissues in human CRC (Della Vittoria Scarpati et al., 2014). A recent study by Zhao and coworkers demonstrated that the expression of miR-192-5p is downregulated in CRC, and the knockdown of miR-192-5p can compromise the tumor suppressive effect of the sh-IncRNA, FTX, indicating the anti-tumor effect of miR-192-5p in CRC (Zhao et al., 2020a). Additionally, miR-192-5p represses glycolysis by regulating the expression of sushi-repeat-containing protein X-linked 2 (SRPX2) in colon cancer cells (Zhao et al., 2018). Intriguingly, the metabolites produced by intestinal microflora can stimulate the expression of miR-192-5p, which subsequently inhibits the proliferation of colon cancer cells via the RhoA–ROCK–LIMK2 pathway (Huang et al., 2020). A recent study by Tavakolian and coworkers demonstrated that the expression of miR-192-5p is significantly reduced in tissues of human gastric cancer, suggesting that miR-192-5p may play an important role in gastric cancer (Tavakolian et al., 2020). Consistently, vital studies have demonstrated that miR-192-5p plays a role in the resistance of EC and gastric cancer to chemotherapy, which reverses cisplatin resistance by targeting ERCC3 and ERCC4 in gastric cancer lines (Hummel et al., 2014; Xie et al., 2019).

In general, miR-192-5p is distributed in different regions of the digestive tract and has diverse functions in regulating disease progression. But there is still no valid evidence for confirming the role of miR-192-5p in diseases of the digestive system, and further mechanistic studies are needed to perform.

**Diseases of the Circulatory System**

Myocardial fibrosis is a feature of various cardiovascular diseases, which may result in heart failure, arrhythmias, and sudden death (Zile and Brutsaert, 2002). The levels of circulating miR-192-5p are upregulated in patients with hypertrophic cardiomyopathy with diffuse myocardial fibrosis and atrial fibrillation (AF), implying that miR-192-5p may be a potential regulator of heart diseases (Natsume et al., 2018) (Fang et al., 2015). The cardiac sodium channel, Nav1.5, is encoded by the SCN5A gene, and can lead to lethal ventricular arrhythmias, sudden death, and AF, when mutated. A study by Zhao and coworkers confirmed that the levels of miR-192-5p are abnormally increased in human AF tissues, which is accompanied by a marked downregulation in the expression of SCN5A/Nav1.5. Mechanistically, miR-192-5p can bind to the 3′-UTR region of SCN5A, and repress the expression of SCN5A/Nav1.5, thereby aggravating arrhythmia (Zhao et al., 2015). In hypoxia/reoxygenation (H/R)-induced apoptosis of H9c2 cardiomyocytes, the overexpression of miR-192-5p promoted apoptosis by targeting FABP3, indicating a potential regulatory role of miR-192-5p in I/R-induced myocardial injury (Zhang et al., 2017). Moreover, the expression of the KCNQ1OT1 IncRNA is downregulated in rats with sepsis-induced myocardial injury, accompanied by an increased expression of miR-192-5p. Functionally, the knockdown of miR-192-5p inhibits LPS-induced apoptosis in H9c2 cells by targeting the XIAP protein. Mechanistically, KCNQ1OT1 protects against LPS-induced myocardial injury by regulating the miR-192-5p/XIAP axis (Sun et al., 2020). Moreover, a recent study also revealed that the expression of miR-192-5p is related to apoptosis in murine myocardial infarction (Ma et al., 2018). In short, miR-192-5p could be a promising therapeutic target.
TABLE 2 | the expression and role of miR-192-5p in different human cancers. NA, not available.

| Human system      | Tumor type | miR-192-5p | Role               | References                                |
|-------------------|------------|------------|--------------------|-------------------------------------------|
| Respiratory       | NPC        | Up         | NA                 | Zou et al. (2020)                         |
|                   | NSCLC      | Down       | Tumor suppressor   | Ye et al. (2015)                          |
|                   | LUAD       | Up         | NA                 | Xue et al. (2020)                         |
| Digestive         | HCC        | Controversy| NA                 | Yan-Chun et al. (2017), Gu et al. (2019), and Zhu et al. (2019) |
|                   | Esophageal cancer | Up       | Oncogene          | Bansal et al. (2014), Huang et al. (2017) |
|                   | Colorectal cancer | Controversy| NA                  | Delia Vittoria Scarpati et al. (2014), Zhao et al. (2020a) |
|                   | Gastric cancer | Down       | Tumor suppressor   | Xie et al. (2019), Tavakolian et al. (2020) |
| Urinary           | BC         | Down       | Tumor suppressor   | Ji et al. (2018)                          |
| Reproductive      | Breast cancer | Controversy| NA                 | Kim et al. (2016), Chen et al. (2018), Fang et al. (2018), and Zhang et al. (2019) |
|                   | Cervical cancer | Up        | NA                 | Kori and Yalcin Arga (2018)               |
|                   | Ovarian cancer | Up        | Oncogene          | Liu W et al. (2017)                       |
|                   | Prostate cancer | Up        | Oncogene          | Chen ZJ et al. (2019)                     |
| Endocrine         | Pancreatic cancer | Up    | NA                 | Zhou X et al. (2018), Zhou X et al., 2019 |
| Motor             | Osteosarcoma | Down       | Tumor suppressor   | Zhou S et al. (2019)                      |

for treating arrhythmia and cardiac injury induced by various factors.

Diseases of the Urinary System Kidney Injury

It has been reported that the levels of miR-192-5p are abundant in the renal cortex of rats, and miR-192-5p is preferentially expressed in the proximal tubules than in the glomeruli, which regulates the activity of the β1 subunit of Na+/K+-ATPase (ATP1B1) in renal tubules (Tian et al., 2008; Mladinov et al., 2013). Given the important role of miR-192-5p in normal kidneys, the disruption of miR-192-5p by various damaging factors may induce the development of kidney disease. In 2014, a study by Kanki and coworkers demonstrated that urinary miR-192-5p is especially upregulated in rats with cisplatin-induced injury to the proximal tubules, and maybe a potential noninvasive biomarker for assessing nephrotoxicity (Kanki et al., 2014). Correspondingly, the levels of miR-192-5p resumed to nearly normal in cisplatin-induced murine acute kidney injury (AKI) following oral therapy with the nanoparticle urolithin A (UA), a gut metabolite of the dietary tannin, ellagic acid (Zou D et al., 2019). Besides, one important study by Chen and coworkers demonstrated that the levels of miR-192-5p increase ectopically in vancomycin (VAN)-induced AKI and in the VAN-treated human renal tubular epithelial cell line, HK-2. Functionally, miR-192-5p silencing in HK-2 repressed VAN-induced apoptosis and caspase activity and the inhibition of miR-192-5p in mice alleviated VAN-induced AKI. Mechanistically, p53 acted as an upstream regulator that modulated the expression of miR-192-5p in response to VAN-induced nephrotoxicity (Chen et al., 2016). More importantly, Zou and coworkers identified that the urinary levels of miR-192-5p are significantly elevated in rats with I/R-induced kidney injury 72 h post-operation, which was earlier than the time of elevation of kidney injury molecule-1 (KIM-1), indicating that miR-192-5p may promote kidney injury (Zou et al., 2017).

Interestingly, the levels of miR-192 are increased in the glomeruli of mice with type 1 (streptozotocin-injected) and type 2 (db/db) diabetes, which is accompanied by the upregulation of TGF-β and col1a2. Mechanistic studies have indicated that miR-192-5p promotes TGF-β-induced collagen deposition in diabetic kidneys disease by targeting the E-box repressor, SMAD-interacting protein 1 (SIP1) (Kato et al., 2007). These studies have highlighted that miR-192-5p may serve as a differential regulator of acute and chronic kidney diseases. Contrary to the aforementioned role of miR-192-5p, the study by Baker and coworkers demonstrated that the expression of miR-192-5p is downregulated in the kidney tissues of patients with hypertension and hypertensive nephrosclerosis, and the knockdown of miR-192-5p in either rat or mice exacerbated the hypertension induced by a high-salt diet. Consistently, another study demonstrated that miR-192-5p protects kidneys against hypertension by targeting ATP1B1, thereby regulating the activity of Na+/K+-ATPase (Baker et al., 2019).

In conclusion, miR-192-5p may serve as a vital promising diagnostic marker of kidney injury, and further studies are necessary for elucidating the precise mechanisms underlying the activity of miR-192-5p. And more detailed studies are necessary for elucidating the reason underlying the contradictions in the levels of miR-192-5p in various kidney diseases.

Other Diseases

It has been reported that bladder cancer (BC) is the 10th most common type of cancer globally, with an estimated 549,000 new cases and 200,000 deaths in 2018, which has a strong male predominance (Bray et al., 2018). In 2018, Ji and coworkers reported for the first time that the levels of miR-192-5p are gradually downregulated in human BC tissues as the disease aggravates, and gain-of-function of it can repress the growth of BC cells by targeting the transcription factor Yin Yang 1 (YY1) (Ji et al., 2018). This study suggests that miR-192-5p may be a potential regulator in progression of BC, but there is still no valid data to confirm its effect on BC. Therefore, further studies are necessary for elucidating the function and mechanism underlying the role of miR-192-5p in BC.

Diseases of the Reproductive System

It is widely acknowledged that breast cancer is the most common malignancy in women reproductive system. According to the
global cancer statistics in 2018, there are approximately 2.1 million newly diagnosed female breast cancer cases, suggesting almost 1 in 4 cancer cases among women, which badly threatens the health of women globally (Bray et al., 2018). Breast cancer is frequently treated by targeting estrogen receptor α (ERα) in various patients, including those treated with tamoxifen (Osborne and Schiff, 2011). Notably, a study by Kim and coworkers demonstrated that the levels of miR-192-5p in patients with recurring breast cancer are higher following treatment with tamoxifen. Functionally, miR-192-5p directly reduces the expression of ERα and promotes tamoxifen resistance in ERα-positive breast cancer cells. Interestingly, Kim et al. reported that miR-192-5p is regulated by lymphocyte antigen six complex (LY6K), which aggravates the progression of breast cancer by negatively correlating with the expression of ERα (Kim et al., 2016). Moreover, the levels of miR-192-5p are relatively higher in the serum of patients with breast cancer than those of patients with benign disease and MDA-MB-231 triple-negative breast cancer cells, signifying the potential role of miR-192-5p in breast cancer (Chen et al., 2018; Fang et al., 2018). However, a study by Zhang and coworkers demonstrated that miR-192-5p promotes the sensitivity of breast cancer cells to doxorubicin treatment by inducing apoptosis (Zhang et al., 2019). Therefore, it remains controversial whether miR-192-5p can be an oncogene or tumor suppressor in breast cancer, and further studies are needed to perform in order to identify the role of miR-192-5p.

More importantly, recent studies have indicated that apart from breast cancer, the expression of miR-192-5p is also dysregulated in cervical, ovarian, and prostate cancers (Chen ZJ et al., 2019; Kori and Yalcin Arga, 2018; Liu W et al., 2017). Prostate cancer is one of the malignant cancers among men. It is estimated that there is almost 1.3 million new cases of prostate cancer and 359,000 associated deaths globally in 2018, which ranks as the second most frequent cancer and the fifth leading cause of cancer death in men (Bray et al., 2018). Thus, finding an efficient biomarker is necessary for predicting the occurrence of prostate cancer. Fortunately, a recent study by Chen and coworkers reported that the expression of miR-192-5p is aberrantly increased in prostate cancer tissues, and the enhanced expression of miR-192-5p promotes the proliferation of prostate cancer cells in vitro (Chen ZJ et al., 2019). Additionally, bioinformatics analyses have revealed that miR-192-5p is associated with ubiquitin-associated and SH3 domain-containing B (UBASH3B), a poor prognostic marker of prostate cancer (Wang et al., 2019). These two studies reveal the possible regulatory role of miR-192-5p in prostate cancer. However, owing to the lack of studies, there is still a controversy regarding the promotive or protective role of miR-192-5p in diseases of the reproductive system, and further studies are needed to clarify the function and mechanism of miR-192-5p.

**Diseases of the Endocrine System**

Physiologically, miR-192-5p is abundant in human pancreatic islets and enriched β-cell populations, indicating the potential involvement of miR-192-5p in diabetes and other pancreatic diseases (van de Bunt et al., 2013). Increasing evidence suggests that the miR-192-5p in biofluids, including the serum and urine, is associated with the presence and incidence of diabetes (Argyropoulos et al., 2015; Jaeger et al., 2018). Besides, miR-192-5p may be a target of traditional Chinese medicine. Jiang Tang Xiao Ke (JTXXK) Granules a Chinese medicine, has been reported to exert therapeutic effects by altering the expression of numerous miRNAs in KKAY diabetic mice, including the upregulated expression of miR-192-5p (Mo et al., 2017). Additionally, the plasma levels of miR-192-5p are significantly increased in patients with type 2 diabetes on short-term intensive insulin therapy (IIT), which is accompanied by an improvement of β-cell function (Nunez Lopez et al., 2019). Meaningfully, miR-192-5p was reported to be regulated by the circular RNA, HIPK3, in two diabetes-associated metabolic disorders, namely, hyperglycemia and insulin resistance. It has been demonstrated that the expression of miR-192-5p is reduced in the liver of diabetic mice and oleate-treated HepG2 cells. The inhibition of miR-192-5p promotes hepatic steatosis and insulin resistance by targeting FOXO1 (Cai et al., 2019). A study revealed that methane-rich saline alleviated diabetic retinopathy (DR), a common complication of diabetes mellitus (DM), in a streptozotocin-induced rat model of diabetes, by increasing the retinal levels of miR-192-5p, which is associated with apoptosis and the tyrosine kinase signaling pathway (Wu et al., 2015). In general, miR-192-5p could be a candidate biomarker of the prognosis of diabetes. Some encouraging reports indicate that the expression of miR-192-5p is abnormally increased in the serum of patients with pancreatic cancer and is also present in exosomes (Zhou X et al., 2018; Zou X et al., 2019). Therefore, miR-192-5p could be a promising therapeutic target for the treatment of diseases of the endocrine system, necessitating the detection of the serum levels of miR-192-5p.

**Diseases of the Nervous System**

Recent studies reveal that miR-192-5p is related to certain diseases of the nervous system, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis, tuberous sclerosis, peripheral nerve injury, and depression (Trelinska et al., 2016; Rahman et al., 2019; Tang et al., 2019; Liu et al., 2020). A study by Tang et al. demonstrated that the overexpression of miR-192-5p rescues cognitive impairment and repairs neural function in a murine model of chronic unpredictable mild stress (CUMS)-induced depression. Mechanistically, miR-192-5p suppresses the TGF-β1 signaling pathway by targeting fibulin (Fbln)-2, a key medium for the neurogenic action of TGF-β1 in neural stem cells (Tang et al., 2019). Inconsistent with the protective role of miR-192-5p in depression, the suppressed expression of miR-192-5p could alleviate neuronal apoptosis and promote the recovery and regeneration of peripheral nerve injury by targeting XIAP in rats with injury to the left sciatic nerve (Liu et al., 2020). Baicalin, a constituent of medical herbs, was reported to inhibit 6-hydroxydopamine-induced neurotoxicity by repressing the expression of miR-192-5p in the PC12 cell model of Parkinson’s disease (PD) (Kang et al., 2019). Although emerging roles of miR-192-5p in diverse diseases of the
nervous system have been gradually elucidated, further studies are necessary for identifying the precise mechanisms.

**Diseases of the Motor System**

It has been reported that rheumatoid arthritis (RA) is a chronic, systemic inflammatory joint disease that affects the motor system and threatens the health of estimated 1.5 million people in U.S adults (Scott et al., 2010). Noteworthily, a recent study by Zheng and coworkers indicated that exosomal miR-192-5p, secreted by bone marrow-derived mesenchymal stem cells (BMSCs), could delay the inflammatory response by suppressing the expression of ras-related C3 botulinum toxin substrate 2 (RAC2) in collagen-induced arthritis (CIA) (Zheng et al., 2020). Moreover, miR-192-5p was reported to inhibit proliferation and induce the apoptosis of human rheumatoid arthritis fibroblast-like synoviocytes (FLS) by targeting caveolin 1, suggesting a pro-inflammatory function and destructive role of miR-192-5p in RA (Li et al., 2017).

It has been reported that osteosarcoma is the most common malignant tumor in children and adolescents, with the high incidence for 2-3 million per year (Biazzo and De Paolis, 2016). Fortunately, the study by Zhou and coworkers indicated that miR-192-5p represses the proliferation, migration, and invasion of osteosarcoma cells by inhibiting ubiquitin-specific protease 1 (USP1), suggesting the important regulatory role of miR-192-5p in osteosarcoma (Zhou S et al., 2018). However, there is still a long way to identify the function and mechanism of miR-192-5p, and further studies are necessary for elucidating the mechanism underlying the role of miR-192-5p in the progression of osteosarcoma.

**CONCLUSION**

Extensive studies on miR-192-5p have provided valuable knowledge regarding the regulatory functions of miR-192-5p and the mechanisms underlying its role in various cell types and numerous human diseases (Table 1). As a conserved and abundant miRNA, miR-192-5p has been widely studied in mammals, and has diverse roles that are mediated by binding to the 3'-UTR of the target mRNA in different diseases. Recent studies have gradually unveiled the novel upstream regulators of miR-192-5p, including circRNA and IncRNA, which may explain why the levels of miR-192-5p differ among various diseases.

Controversially, it has been reported that the expression of miR-192-5p is upregulated or downregulated in different human cancers, by acting as an oncogene or tumor suppressor (Table 2). For instance, the majority of studies have suggested that miR-192-5p acts as a tumor suppressor in NSCLC. It has been confirmed that the expression of miR-192-5p is maintained at an inadequate level in the serum of NSCLC, and functional studies have indicated that miR-192-5p suppresses the proliferation, migration, and invasion of lung cancer cell lines by targeting different critical molecules, including c-Myc and TRIM44. Moreover, important studies have demonstrated that curcumin exerts a protective effect in NSCLC by upregulating miR-192-5p in a p53-dependent manner. However, owing to the flexibility of miR-192-5p in different systems of the human body, scientists may hold controversial views regarding miR-192-5p in certain diseases, including HCC and chemotherapy-resistant breast cancer. At present, there are too many studies on miR-192-5p in human diseases, and the functions of miR-192-5p are different in many above reported diseases, which will bring a problem that, for example, systemic knockout or overexpression of miR-192-5p will cause other side effects, rather than specific targeting of a certain disease. Besides, in the study of miR-192-5p, there is a lack of large-sample clinical data, which is unbefitting to deepen our understanding of the role of miR-192-5p. But we believe that a comprehensive review of miR-192-5p in different human diseases will encourage the clinical investigation and application of miR-192-5p in diagnosing and predicting human diseases.

**AUTHOR CONTRIBUTIONS**

FR and YY drafted the manuscript; XC checked the figures and tables and revised the manuscript; GF edited and added the constructive suggestions on the manuscript. All authors approved the final version of the manuscript.

**ACKNOWLEDGMENTS**

We appreciate the support of Hangzhou Women’s Hospital. We would like to thank Editage (www.editage.com) for English language editing.

**REFERENCES**

Argyropoulos, C., Wang, K., Bernardo, J., Ellis, D., Orchard, T., Galas, D., et al. (2015). Urinary MicroRNA profiling predicts the development of microalbuminuria in patients with type 1 diabetes. J. Clin. Med. 4, 1498–1517. doi:10.3390/jcm4071498

Baker, M. A., Wang, F., Liu, Y., Kriegel, A. J., Geurts, A. M., Usa, K., et al. (2019). miR-192-5p in the kidney protects against the development of hypertension. Hypertension 73, 399–406. doi:10.1161/HYPERTENSIONAHA.118.11875

Bansal, A., Hong, X., Lee, I. H., Krishnadath, K. K., Mathur, S. C., Gunewardena, S., et al. (2014). MicroRNA expression can be a promising strategy for the detection of Barrett’s esophagus: a pilot study. Clin. Transl. Gastroenterol. 5, e65. doi:10.1038/ctg.2014.17

Bartel, D. P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297. doi:10.1016/s0092-8674(04)00045-5

Biazzo, A., and De Paolis, M. (2016). Multidisciplinary approach to osteosarcoma. Acta Orthop. Belg. 82, 690–698.

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., and Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. doi:10.3322/caac.21492

Bruckmueller, H., Martin, P., Kehler, M., Haensch, S., Ostrowski, M., Drozdzik, M., et al. (2017). Clinically relevant multidrug transporters are regulated by microRNAs along the human intestine. Mol. Pharm. 14, 2245–2253. doi:10.1021/acs.molpharmaceut.7b00076

Brunetto, M. R., Cavallone, D., Oliveri, F., Moriconi, F., Colombatto, P., Coco, B., et al. (2014). A serum microRNA signature is associated with the immune...
control of chronic hepatitis B virus infection. PLoS One 9, e110782. doi:10.1371/journal.pone.0110782
Bushel, Cornami, G., Pancreri, R., Dinelli, M., Biondi, A., Mancuso, C., Meneveri, R., et al. (2015). miRNA-regulated gene expression differs in celiac disease patients according to the age of presentation. Genes Nutr. 10, 482. doi:10.1007/s12263-015-0482-2
Bushel, P. R., Caiment, F., Wu, H., O’Lone, R., Day, F., Calley, J., et al. (2018). RATERmiRs: the rat atlas of tissue-specific and enriched miRNAs database. BMC Genomics 19, 825. doi:10.1186/s12864-018-5220-x
Cai, H., Jiang, Z., Yang, X., Lin, J., Cai, Q., and Li, X. (2019). Circular RNA HIPK3 contributes to hyperglycemia and insulin homeostasis by sponging miR-192-5p and upregulating transcription factor forkhead box O1. Endocr. J. 66, 397–408. doi:10.1507/endocrj.EJ19-0271
Caserta, S., Kern, F., Cohen, J., Drage, S., Newbury, S. F., and Llewelyn, M. J. (2016). Circulating plasma microRNAs can differentiate human sepsis and systemic inflammatory response syndrome (SIRS). Sci. Rep. 6, 28006. doi:10.1038/srep28006
Chen, J., Chen, Z., Huang, J., Chen, F., Ye, W., Ding, G., et al. (2018). miR-192 is overexpressed and promotes cell proliferation in prostate cancer. Med. Princ Pract. 28, 124–132. doi:10.1159/000496206
Chua, M. L. K., Wee, J. T. S., Hui, E. P., and Chan, A. T. C. (2016). Nasopharyngeal carcinoma. Lancet 394, 64–80. doi:10.1016/S0140-6736(19)30956-0
Chen, Z. J., Yan, Y. J., Shen, H., Zhou, J. J., Yang, G. H., Liao, Y. X., et al. (2019). Beyond miR-122: identification of MicroRNA alterations in blood during a time course of hepatobiliary injury and biliary hyperplasia in rats. Toxicol. Sci. 150, 3–14. doi:10.1093/toxsci/kfx260
Della Vittoria Scarpati, G., Calura, E., Di Marino, M., Romualdi, C., Beltrame, L., Iguchi, T., Niino, N., Tamai, S., Sakurai, K., and Mori, K. (2017). Comprehensive analysis of circulating microRNA specific to the liver, heart, and skeletal muscle of cynomolgus monkeys. Int. J. Toxicol. 36, 220–228. doi:10.1177/1091581710479737
Enginoglu, F., Roscigno, G., Affinito, A., Nuzzo, S., Scognamiglio, I., Quintavalle, C., et al. (2019). The role of Exo-miRNAs in cancer: a focus on therapeutic and diagnostic applications. Int. J. Mol. Sci. 20, 4687. doi:10.3390/ijms20194687
Jaeger, A., Zollinger, L., Saely, C. H., Suenblin, A., Evangelakos, I., Nasias, D., et al. (2018). Circulating microRNAs -192 and -194 are associated with the presence and incidence of diabetes mellitus. Sci. Rep. 8, 14274. doi:10.1038/s41598-018-32274-9
Jenal, A., Siegel, R., Xu, J., and Ward, E. (2010). Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300. doi:10.3322/caac.200773
Ji, D., Jiang, L., and Li, Y. (2018). MiR-192-5p suppresses the growth of bladder cancer cells via targeting Yin Yang 1. Hum. Cell 31, 210–219. doi:10.1007/s12263-018-0201-6
Jin, Q., Hong, F., Yang, X., Xu, Y., and Shang, Y. (2015). Curcumin inhibits cell proliferation and induces apoptosis of human non-small cell lung cancer cells through the upregulation of miR-192-5p and suppression of PI3K/Akt signaling pathway. Oncol. Rep. 34, 2782–2789. doi:10.3892/or.2015.4258
Jonas, S., and Izaurralde, E. (2015). Towards a molecular understanding of microRNA-mediated gene silencing. Nat. Rev. Genet. 16, 421–433. doi:10.1038/nrg3965
Kang, C., Wang, L., Kang, M., Liu, X., Fu, Y., and Gao, J. (2019). Baicalin alleviates 6-hydroxydopamine-induced neurotoxicity in PC12 cells by down-regulation of microRNA-192-5p. Brain Res. 1708, 84–92. doi:10.1016/j.braains.2018.12.015
Kanki, M., Moriguchi, A., Sasaki, D., Mitöri, H., Yamada, A., Unami, A., et al. (2014). Identification of urinary miRNA biomarkers for detecting cisplatin-induced proximal tubular injury in rats. Toxicology 324, 158–166. 10.1016/j.tox.2015.05.004
Kato, M., Zhang, J., Wang, M., Lanting, L., Yuan, H., Rossi, J. J., et al. (2007). MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl. Acad. Sci. U.S.A. 104, 3432–3437. doi:10.1073/pnas.0611129104
Kim, Y. S., Park, S. J., Lee, Y. S., Kong, H. K., and Park, J. H. (2016). miRNAs involved in LYY4 and estrogen receptor alpha contribute to tamoxifen-susceptibility in breast cancer. Oncotarget 7, 42261–42273. doi:10.18632/oncotarget.9590
Kori, M., and Yalcin Arga, K. (2018). Potential biomarkers and therapeutic targets in cervical cancer: insights from the meta-analysis of transcriptomics data within network biomolecule perspective. PLoS One 13, e0200717. doi:10.1371/journal.pone.0200717
Krattinger, R., Bostrom, A., Schiöth, H. B., Thasler, W. E., Mwinyi, J., and Kullak-Ublick, G. A. (2016). microRNA-192 suppresses the expression of the farnesoid X receptor. Am. J. Physiol. Gastrointest. Liver Physiol. 310, G1044–G1051. doi:10.1152/ajpgi.00297.2015
Kulcheski, F. R., Christoff, A. P., and Margis, R. (2016). Circular RNAs are miRNA sponges and can be used as a new class of biomarker. J. Biotechnol. 238, 42–51. doi:10.1016/j.jbiotec.2016.09.011
Kumar, S., Shrawat, S. K., Ali, A., Gaur, V., Malik, P. S., Kumar, S., et al. (2020). Identification of differentially expressed circulating serum microRNA for the diagnosis and prognosis of Indian non-small cell lung cancer patients. Curr. Probl. Cancer 44, 100540. doi:10.1016/j.currprobcancer.2020.100540
Lee, Y., Pham, T. X., Bae, M., Hu, S., O’Neill, E., Chin, O. K., et al. (2019). Blackcurrant (Ribes nigrum) prevents obesity-induced nonalcoholic steatohepatitis in mice. Obesity (Silver Spring) 27, 112–120. doi:10.1002/oby.22353
Li, S., Jin, Z., and Lu, X. (2017). MicroRNA-192 suppresses cell proliferation and induces apoptosis in human rheumatoid arthritis fibroblast-like synovocytes by downregulating caveolin 1. Mol. Cell Biochem. 432, 123–130. doi:10.1007/s11010-017-3003-3
Huang, Z., Zhang, L., Zhu, D., Shan, X., Zhou, X., Qi, L. W., et al. (2017). A novel serum microRNA signature to screen esophageal squamous cell carcinoma. Cancer Med. 6, 109–119. doi:10.1002/cam4.973
Hummel, R., Sie, C., Watson, D. I., Wang, T., Ansar, A., Michael, M. Z., et al. (2014). MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. World J. Gastroenterol. 20, 14904–14912. doi:10.3748/wjg.v20.i40.14904
Iguchi, T., Niino, N., Tamai, S., Sakurai, K., and Mori, K. (2017). Comprehensive analysis of circulating microRNA specific to the liver, heart, and skeletal muscle of cynomolgus monkeys. Int. J. Toxicol. 36, 220–228. doi:10.1177/1091581710479737
Ren et al. miR-192-5p in Human Diseases
van de Bunt, M., Gaulton, K. J., Parts, L., Moran, I., Johnson, P. R., Lindgren, C. M., et al. (2013). The miRNA profile of human pancreatic islets and beta-cells and relationship to type 2 diabetes pathogenesis. PLoS One 8, e55272. doi:10.1371/journal.pone.0055272

van der Ree, M. H., Jansen, L., Kruize, Z., van Nuenen, A. C., van Dott, K. A., Takkenberg, R. B., et al. (2017). Plasma MicroRNA levels are associated with hepatitis B antigen status and treatment response in chronic hepatitis B patients. J. Infect. Dis. 215, 1421–1429. doi:10.1093/infdis/jix140

Wang, Z., Wang, Y., Peng, M., and Yi, L. (2019). Urinary-MiRNA in diagnosis and prognosis of pancreatic cancer: a miRNA expression analysis. Gene 727, 181–193. doi:10.1016/j.gene.2018.10.037

Zou, R., Zhao, Y., Huang, Y., Li, W., Wang, Z., Zhan, S., Zhou, M., et al. (2015). Bone marrow-derived mesenchymal stem cells-secreted exosomal microRNA-192-5p delays inflammatory response in rheumatoid arthritis. Int. Immunopharmacol. 78, 105985. doi:10.1016/j.intimp.2019.105985

Zhou, S., Xiong, M., Dai, G., Yu, L., Zhang, Z., Chen, J., et al. (2018). MicroRNA-192-5p suppresses the initiation and progression of osteosarcoma by targeting USP1. Oncol. Lett. 15, 6947–6956. doi:10.3892/ol.2018.9180

Zhou, X., Zou, Y., Huang, Y., Li, W., Wang, Z., Zhang, Z., et al. (2017). Elevated TRIP13 drives the AKT/mTOR pathway to induce the progression of hepatocellular carcinoma via interacting with ACTN4. J. Exp. Clin. Cancer Res. 38, 409. doi:10.1186/s13046-019-1401-y

Zile, M. R., and Brutsaert, D. L. (2002). New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105, 1503–1508. doi:10.1161/1161.hc1202.105290

Zou, D., Ganugula, R., Arora, M., Nabity, M. B., Sheikh-Hamad, D., and Kumar, M. (2019). Oral delivery of nanoparticle urolithin A normalizes cellular stress and improves survival in mouse model of cisplatin-induced AKI. Am. J. Physiol. Ren. Physiol. 317, F1255–F1264. doi:10.1152/ajprenal.00346.2019

Zou, P., Zhu, M., Lian, C., Wang, J., Chen, Z., Zhang, X., et al. (2019). miR-192-5p suppresses the progression of lung cancer bone metastasis by targeting TRIM44. Sci. Rep. 9, 19619. doi:10.1038/s41598-019-56018-5

Zou, X., Wei, J., Huang, Z., Zhou, X., Lu, Z., Zhu, W., et al. (2019). Identification of a six-miRNA panel in serum benefiting pancreatic cancer diagnosis. Cancer Med. 8, 2810–2822. doi:10.1002/cam4.2145

Zou, X., Zhu, D., Zhang, H., Zhang, S., Zhou, X., He, X., et al. (2020). MicroRNA expression profiling analysis in serum for nasopharyngeal carcinoma diagnosis. Gene 727, 144243. doi:10.1016/j.gene.2019.144243

Zou, Y. F., Wen, D., Zhao, Q., Shen, P. Y., Shi, H., Zhao, Q., et al. (2017). Urinary MicroRNA-30c-5p and MicroRNA-192-5p as potential biomarkers of ischemia-reperfusion-induced kidney injury. Exp. Biol. Med. 242, 657–667. doi:10.1177/1535370216685005

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Copyright © 2021 Ren, Yao, Cai and Fang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

ABCC3 ATP binding cassette transporter subfamily C member 3
AD Alzheimer’s Disease
AF atrial fibrillation
AKI acute kidney injury
ALDH3A2 aldehyde dehydrogenase 3 family member A2
ATG7 autophagy related 7
ATP1B1 the β1 subunit of Na+/K+-ATPase
BC bladder cancer
BMSCs bone marrow-derived mesenchymal stem cells
CCI4 carbon tetrachloride
CD Crohn’s disease
CHB chronic hepatitis B
CIA collagen-induced arthritis
circRNA circular RNA
CRC colorectal cancer
CSCs cancer stem cells
CUMS chronic unpredictable mild stress
CXCL2 C-X-C motif chemokine ligand 2
CXCR5 C-X-C chemokine receptor type 5
DM diabetes mellitus
DMF N,N-dimethyl formamide
DR diabetic retinopathy
EAC esophageal adenocarcinoma
EBV Epstein–Barr virus
EC Esophageal cancer
EEN exclusive enteral nutrition
EMT epithelial-to-mesenchymal transition
ER endoplasmic reticulum
ERα estrogen receptor α
ESCC squamous cell carcinoma
FLS fibroblast-like synoviocytes
FOXO1 forkhead box O1
FXR farnesoid X receptor
H/R hypoxia/reoxygenation
HCC hepatocellular carcinoma
HCS healthy controls
HFD high-fat diet
hUC-MSCs human umbilical cord Wharton’s jelly derived mesenchymal stem cell
I/R ischaemia and reperfusion
IC inactive-carriers
IIT intensive insulin therapy
JTXK Jiang Tang Xiao Ke
KCNQ1OT1 strand/antisense transcript 1
KIM-1 kidney injury molecule-1
IncRNA long noncoding RNA
LUAD adenocarcinoma
LUSC squamous cell carcinoma
LY6K squamous cell carcinoma
miRNAs MicroRNAs
MMP-16 matrix metalloproteinase-16
NAFLD nonalcoholic fatty liver disease
NASH nonalcoholic steatohepatitis
NCs normal controls
NOB1 NIN1/RPN12 binding protein 1
NOD2 nucleotide binding oligomerization domain containing 2
NPC Nasopharyngeal carcinoma
NSCLC non-small cell lung cancer
ORF open reading frame
PD parkinson’s disease
PFOA perfluorooctanoic acid
RA Rheumatoid arthritis
RAC2 ras-related C3 botulinum toxin substrate 2
SCD-1 stearoyl-CoA desaturase 1
SEMA3A semaphorin 3A
SGBS Simpson–Golabi–Behmel syndrome
SIP1 SMAD-interacting protein 1
SRPX2 sushi repeat-containing protein X-linked 2
TG triglyceride
TRIM44 tripartite motif 44
TRIP13 thyroid hormone receptor interactor 13
UA urolithin A
UBASH3B ubiquitin-associated and SH3 domain-containing B
USP1 ubiquitin-specific protease 1
VAN vancomycin
VAT visceral adipose tissue
XIAP X-linked inhibitor of apoptosis protein
YY1 Yin Yang 1